Hope E. Uronis

5.5k total citations
119 papers, 2.3k citations indexed

About

Hope E. Uronis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hope E. Uronis has authored 119 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 56 papers in Pulmonary and Respiratory Medicine and 35 papers in Surgery. Recurrent topics in Hope E. Uronis's work include Gastric Cancer Management and Outcomes (33 papers), Colorectal Cancer Treatments and Studies (27 papers) and Pancreatic and Hepatic Oncology Research (26 papers). Hope E. Uronis is often cited by papers focused on Gastric Cancer Management and Outcomes (33 papers), Colorectal Cancer Treatments and Studies (27 papers) and Pancreatic and Hepatic Oncology Research (26 papers). Hope E. Uronis collaborates with scholars based in United States, South Korea and United Kingdom. Hope E. Uronis's co-authors include Johanna C. Bendell, Herbert I. Hurwitz, S. Yousuf Zafar, Amy P. Abernethy, Eileen M. O’Reilly, Mehmet Sitki Copur, Christopher H. Crane, Daniel A. Laheru, Davendra Sohal and Manish A. Shah and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Hope E. Uronis

116 papers receiving 2.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Hope E. Uronis 1.5k 848 628 478 428 119 2.3k
Dieter Koeberle 1.6k 1.1× 739 0.9× 562 0.9× 430 0.9× 271 0.6× 87 2.3k
Monika Klinkhammer‐Schalke 1.4k 0.9× 552 0.7× 616 1.0× 607 1.3× 567 1.3× 171 2.9k
Giles F. Whalen 1.4k 0.9× 573 0.7× 1.1k 1.8× 281 0.6× 504 1.2× 73 2.6k
Desmond Yip 1.6k 1.1× 938 1.1× 498 0.8× 398 0.8× 579 1.4× 162 2.9k
Gauri Varadhachary 1.5k 1.0× 663 0.8× 504 0.8× 600 1.3× 343 0.8× 25 2.1k
Athanasios Pallis 1.5k 1.0× 1.1k 1.3× 265 0.4× 369 0.8× 401 0.9× 103 2.7k
Oscar Bertetto 1.2k 0.8× 639 0.8× 561 0.9× 207 0.4× 318 0.7× 105 2.3k
Roldano Fossati 1.7k 1.1× 1.7k 2.0× 418 0.7× 582 1.2× 367 0.9× 49 3.5k
Eva Segelov 1.4k 1.0× 419 0.5× 417 0.7× 218 0.5× 375 0.9× 158 2.4k
Norbert Marschner 1.3k 0.9× 649 0.8× 258 0.4× 349 0.7× 407 1.0× 153 2.2k

Countries citing papers authored by Hope E. Uronis

Since Specialization
Citations

This map shows the geographic impact of Hope E. Uronis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hope E. Uronis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hope E. Uronis more than expected).

Fields of papers citing papers by Hope E. Uronis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hope E. Uronis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hope E. Uronis. The network helps show where Hope E. Uronis may publish in the future.

Co-authorship network of co-authors of Hope E. Uronis

This figure shows the co-authorship network connecting the top 25 collaborators of Hope E. Uronis. A scholar is included among the top collaborators of Hope E. Uronis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hope E. Uronis. Hope E. Uronis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Merkow, Ryan P., Michael J. Cavnar, Ana Gleisner, et al.. (2025). Minimum Requirements to Safely Establish and Sustain New Hepatic Arterial Infusion Pump Programs: An International Expert Perspective. Annals of Surgical Oncology. 32(6). 4408–4416.
2.
Lee, Keun Wook, Devalingam Mahalingam, Byoung Yong Shim, et al.. (2025). DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B. Nature Communications. 16(1). 6393–6393.
3.
Klempner, Samuel J., Mohamad Bassam Sonbol, Zev A. Wainberg, et al.. (2024). DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. Journal of Clinical Oncology. 43(3). 339–349. 12 indexed citations
4.
Hyland, Kelly A., Caroline S. Dorfman, Samuel I. Berchuck, et al.. (2023). mHealth Coping Skills Training for Symptom Management (mCOPE) for colorectal cancer patients in early to mid-adulthood: Study protocol for a randomized controlled trial. Contemporary Clinical Trials Communications. 33. 101126–101126. 1 indexed citations
5.
6.
7.
8.
Uronis, Hope E., et al.. (2022). A narrative review of the evolving role of immunotherapy in the management of esophageal and gastric cancer. Journal of Gastrointestinal Oncology. 13(4). 2007–2019. 4 indexed citations
9.
Moehler, Markus, Jaffer A. Ajani, Thomas Zander, et al.. (2021). 1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577. Annals of Oncology. 32. S1045–S1046. 5 indexed citations
10.
Klempner, Samuel J., Cynthia A. Sirard, V.K. Chiu, et al.. (2021). 1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial. Annals of Oncology. 32. S1048–S1049. 3 indexed citations
11.
DeVito, Nicholas C., Kyle C. Strickland, James L. Abbruzzese, et al.. (2021). A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis. AME Case Reports. 5. 14–14. 1 indexed citations
12.
Kelly, Ronan J., Jaffer A. Ajani, Thomas Zander, et al.. (2020). LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. Annals of Oncology. 31. S1193–S1194. 37 indexed citations
13.
14.
Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, et al.. (2019). A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. Cancer Chemotherapy and Pharmacology. 83(6). 1025–1035. 7 indexed citations
15.
Eng, Cathy, Marwan Fakih, Manik Amin, et al.. (2017). P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer. Annals of Oncology. 28. v181–v182. 4 indexed citations
16.
Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2015). Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. Molecular Cancer Therapeutics. 14(4). 1048–1056. 18 indexed citations
17.
Borad, Mitesh J., Shantan Reddy, Nathan Bahary, et al.. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology. 23. ix224–ix224. 3 indexed citations
18.
Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, et al.. (2012). A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70(1). 95–102. 33 indexed citations
19.
Uronis, Hope E. & Amy P. Abernethy. (2008). Oxygen for relief of dyspnea: what is the evidence?. Current Opinion in Supportive and Palliative Care. 2(2). 89–94. 9 indexed citations
20.
Uronis, Hope E., David C. Currow, & Amy P. Abernethy. (2006). Palliative management of refractory dyspnea in COPD. International Journal of COPD. 1(3). 289–304. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dieter Koeberle Breakdown of academic impact, for papers by Monika Klinkhammer‐Schalke Breakdown of academic impact, for papers by Giles F. Whalen Breakdown of academic impact, for papers by Desmond Yip Breakdown of academic impact, for papers by Gauri Varadhachary Breakdown of academic impact, for papers by Athanasios Pallis Breakdown of academic impact, for papers by Oscar Bertetto Breakdown of academic impact, for papers by Roldano Fossati Breakdown of academic impact, for papers by Eva Segelov Breakdown of academic impact, for papers by Norbert Marschner
Rankless by CCL
2026